• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Vicarious Surgical Announces Election of New Directors

    6/30/25 6:45:00 AM ET
    $GSAT
    $IRIX
    $JNJ
    $MITK
    Telecommunications Equipment
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $GSAT alert in real time by email

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the election of Fuad Ahmad and Joseph Doherty to the Vicarious Surgical Board of Directors at the Company's 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Vicarious Surgical Board of Directors effective as of the Annual Meeting.

    "On behalf of the board, I am thrilled to welcome Fuad and Joseph to the Vicarious team. Their decades of experience and insight will be instrumental as we continue our advance towards our clinical trial and the eventual commercialization of our platform" said Adam Sachs, CEO and Co-Founder of Vicarious Surgical. "I would also like to thank Ric for his 5-years of dedicated service and invaluable guidance. His tenure has left a lasting positive impact on the Company."

    Mr. Ahmad has been a partner at FLG Partners, a CEO and CFO consulting practice and board advisory services firm, since 2013. From November 2020 to March 2025, he served as CFO of Iridex Corporation (NASDAQ:IRIX), a medical device company. Prior to that, Mr. Ahmad served as CFO at each of Mitek Systems (NASDAQ:MITK), Vaxart, Inc. (NASDAQ:VXRT), Cutera, Inc. and Telenav, Inc. Prior to joining FLG Partners, he served as CFO of Sezmi Corporation, a Morgenthaler Ventures-backed cloud-based software platform. Prior to his service with Sezmi Corporation, Mr. Ahmad served as Senior Vice President and CFO of Globalstar Inc. (NASDAQ:GSAT), a public company that builds and operates low-earth orbit satellite-based digital telecommunications systems. In this role, Mr. Ahmad was involved in the initial fundraising activities related to building and launching Globalstar's satellite telecommunications system, including its IPO and various public market and private financing initiatives totaling more than $1.5 billion. Mr. Ahmad graduated from Brigham Young University with a Bachelor of Science in Finance.

    Mr. Doherty has served as CEO of the Worcester City Campus Corporation, a not-for-profit corporation whose base corporate purpose is to foster, promote and support the University of Massachusetts since January 2025. Since 2020, Mr. Doherty has served as a teacher at Saint John's High School, and since March 2022, Mr. Doherty has also served as a member of the board of directors of Immertec, a software company that creates immersive and interactive experiences for training in healthcare. From 2021 to 2025, he served as the Director for the BOLT initiative at the Massachusetts Biomedical Initiative (MBI), a nonprofit life science startup incubator. From January 2019 to August 2020, he served as the President of Scapa Healthcare, and from January 2019 to May 2020, he was a member of the board of directors of Scapa Group, a publicly traded company on AIM, a market of the London Stock Exchange plc. There, he oversaw a B2B business focused on developing and manufacturing medical devices and consumer wellness products for global market leaders. From 2015 to 2019, Mr. Doherty served in roles of increasing responsibility, including as President of Olympus Surgical Technologies America, a medical device subsidiary of Olympus Corporation of the Americas. He also spent over 24 years with Johnson & Johnson (NYSE:JNJ) and held various roles with increasing responsibilities, ultimately serving as the Vice President of Integration and Transformation. Mr. Doherty received a Bachelor of Science in Engineering from the United States Military Academy at West Point and a Master of Business Administration from Nichols College.

    About Vicarious Surgical

    Founded in 2014, Vicarious Surgical is a next generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company's novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, Innovation Endeavors, Jerry Yang's AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang's E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding the Company's expectations for its advancement toward a clinical trial and commercialization, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of the Company's Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of the Company's initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product and service development activities; the potential attributes and benefits of the Company's product candidates and services; the Company's ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing license, manufacture, supply and distribution agreements; the Company's ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company's business, financial condition and results of operations; the Company's intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company's filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250630391787/en/

    Investor Contact

    Marissa Bych

    Gilmartin Group

    [email protected]

    Media Inquiries

    [email protected]

    Get the next $GSAT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GSAT
    $IRIX
    $JNJ
    $MITK

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Johnson & Johnson
    $JNJ
    12/10/2024$166.00Neutral
    BofA Securities
    Johnson & Johnson
    $JNJ
    11/15/2024$190.00Outperform
    Wolfe Research
    Mitek Systems Inc.
    $MITK
    9/4/2024$17.00 → $9.50Buy → Hold
    Jefferies
    Vaxart Inc
    $VXRT
    8/15/2024$4.00Outperform
    Oppenheimer
    Johnson & Johnson
    $JNJ
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    5/30/2024$160.00Neutral
    Goldman
    More analyst ratings

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Innovative Medicine, R&D Reed John C sold $3,129,830 worth of shares (19,137 units at $163.55), decreasing direct ownership by 64% to 10,658 units (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      7/18/25 4:12:41 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Mercer Patrick covered exercise/tax liability with 4,243 shares, decreasing direct ownership by 1% to 415,857 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      7/15/25 6:02:23 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • New insider Pinto Daniel E claimed no ownership of stock in the company (SEC Form 3)

      3 - JOHNSON & JOHNSON (0000200406) (Issuer)

      7/8/25 5:31:26 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mitek to Report Fiscal 2025 Third Quarter Financial Results on Aug. 7, 2025

      Mitek Systems, Inc. (NASDAQ:MITK), a global leader in digital identity verification and fraud prevention, today announced that it will release its financial results for the third quarter of fiscal year 2025, which ended June 30, 2025, after the U.S. market closes on Thursday, Aug. 7, 2025. Mitek will host a conference call and live webcast to discuss the results at 2 p.m. PT (5 p.m. ET). Mitek CEO Ed West and CFO Dave Lyle will lead the call, followed by a Q&A session. Conference Call and Webcast Details Event: Mitek Fiscal 2025 Third Quarter Financial Results Date: Thursday, Aug. 7, 2025 Time: 2 p.m. PT (5 p.m. ET) Participants are encouraged to pre-register for the webcast by clic

      7/25/25 9:00:00 AM ET
      $MITK
      Computer peripheral equipment
      Technology
    • Johnson & Johnson to Participate in the 2025 Wells Fargo Healthcare Conference

      Johnson & Johnson (NYSE:JNJ) will present at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025. Management will participate in a Fireside Chat at 11:50 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20250724655759/en/ Media contact: [email protected] Investor contact: [email protected]

      7/24/25 4:30:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

      - Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings Panel Meeting Scheduled on August 14, 2025 - SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it filed a preliminary proxy statement with an updated reverse stock split proposal. The filing of the preliminary proxy statement follows the trading suspension of the Company's comm

      7/24/25 4:01:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Vaxart Inc

      PRE 14A - Vaxart, Inc. (0000072444) (Filer)

      7/25/25 10:26:15 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Johnson & Johnson

      10-Q - JOHNSON & JOHNSON (0000200406) (Filer)

      7/24/25 4:04:24 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 13F-HR filed by Johnson & Johnson

      13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

      7/22/25 12:33:19 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Moore William M bought $19,372 worth of shares (20,000 units at $0.97), increasing direct ownership by 12% to 188,650 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/16/25 1:44:46 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President and CEO Mercer Patrick bought $240 worth of shares (250 units at $0.96), increasing direct ownership by 0.06% to 386,730 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/13/25 2:43:38 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Moore William M bought $29,121 worth of shares (30,000 units at $0.97), increasing direct ownership by 22% to 168,650 units (SEC Form 4)

      4 - IRIDEX CORP (0001006045) (Issuer)

      6/13/25 1:28:06 PM ET
      $IRIX
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson upgraded by Erste Group

      Erste Group upgraded Johnson & Johnson from Hold to Buy

      7/23/25 8:55:43 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

      5/13/25 8:56:13 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on Johnson & Johnson with a new price target

      BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

      12/10/24 8:28:42 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Leadership Updates

    Live Leadership Updates

    See more
    • Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

      Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

      6/10/25 4:51:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxart Appoints Jeroen Grasman as Chief Financial Officer

      - Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced the appointment of Jeroen Grasman as its Chief Financial Officer (CFO), effective May 19, 2025. Mr. Grasman succeeds Phillip Lee, who is resigning from his position as CFO for personal reasons. To ensure a smooth transition, Mr. Lee will remain with the Company as a non-executive employee through June 1, 2025. "We are delighted to welcome Jeroen to the Vaxart team," said Steven Lo, Chief Executive Officer of Vaxart. "His extensive financial expertise and proven track record in the biotech sector, includ

      5/13/25 4:01:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mitek Appoints Industry Expert Garrett Gafke as Chief Operating Officer to Accelerate Growth and Innovation

      Mitek Systems, Inc. (NASDAQ:MITK), a global leader in digital identity verification, fraud prevention, and biometrics, today announced the appointment of Garrett Gafke as Chief Operating Officer. A recognized entrepreneur and Fortune 500 executive, Mr. Gafke brings decades of experience scaling and transforming technology businesses across risk, fraud, and digital identity. As part of Mitek's strategy to accelerate growth through innovation and operational excellence, the appointment of Mr. Gafke represents a pivotal forward step. A proven leader in category-defining technology, he joins the executive team with a clear mandate: to streamline operations, accelerate innovation, and expand th

      4/28/25 8:00:00 AM ET
      $MITK
      Computer peripheral equipment
      Technology

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Financials

    Live finance-specific insights

    See more
    • Mitek to Report Fiscal 2025 Third Quarter Financial Results on Aug. 7, 2025

      Mitek Systems, Inc. (NASDAQ:MITK), a global leader in digital identity verification and fraud prevention, today announced that it will release its financial results for the third quarter of fiscal year 2025, which ended June 30, 2025, after the U.S. market closes on Thursday, Aug. 7, 2025. Mitek will host a conference call and live webcast to discuss the results at 2 p.m. PT (5 p.m. ET). Mitek CEO Ed West and CFO Dave Lyle will lead the call, followed by a Q&A session. Conference Call and Webcast Details Event: Mitek Fiscal 2025 Third Quarter Financial Results Date: Thursday, Aug. 7, 2025 Time: 2 p.m. PT (5 p.m. ET) Participants are encouraged to pre-register for the webcast by clic

      7/25/25 9:00:00 AM ET
      $MITK
      Computer peripheral equipment
      Technology
    • Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

      Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po

      7/16/25 6:25:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

      2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77 Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint b

      7/16/25 6:20:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSAT
    $IRIX
    $JNJ
    $MITK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mitek Systems Inc.

      SC 13G/A - MITEK SYSTEMS INC (0000807863) (Subject)

      11/12/24 12:48:30 PM ET
      $MITK
      Computer peripheral equipment
      Technology
    • SEC Form SC 13G filed by Johnson & Johnson

      SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

      4/10/24 5:12:55 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vaxart Inc (Amendment)

      SC 13G/A - Vaxart, Inc. (0000072444) (Subject)

      2/13/24 5:16:04 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care